Holen Sie sich die Stockscreener-App
190.11
0.55%
1.04
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$189.07
Offen:
$188.6
24-Stunden-Volumen:
170.88K
Relative Volume:
0.89
Marktkapitalisierung:
$3.74B
Einnahmen:
$152.42M
Nettoeinkommen (Verlust:
$45.24M
KGV:
75.74
EPS:
2.51
Netto-Cashflow:
$6.97M
1W Leistung:
-2.92%
1M Leistung:
-2.56%
6M Leistung:
+67.26%
1J Leistung:
+75.35%
1-Tages-Spanne:
$186.47
$192.48
1-Wochen-Bereich:
$186.47
$196.04
52-Wochen-Spanne:
$93.58
$212.49
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Firmenname
Ligand Pharmaceuticals Inc
Sektor
Branche
Telefon
858-550-7500
Adresse
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Vergleichen Sie LGND mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
190.11 | 3.72B | 152.42M | 45.24M | 6.97M | 2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Citigroup | Buy |
| 2025-04-10 | Eingeleitet | Stifel | Buy |
| 2024-10-03 | Eingeleitet | Oppenheimer | Outperform |
| 2024-07-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-04-14 | Fortgesetzt | Stephens | Overweight |
| 2021-02-04 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-06 | Eingeleitet | Barclays | Overweight |
| 2020-03-24 | Herabstufung | Argus | Buy → Hold |
| 2020-03-10 | Eingeleitet | Guggenheim | Neutral |
| 2020-02-06 | Eingeleitet | The Benchmark Company | Buy |
| 2019-09-19 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-03 | Bestätigt | H.C. Wainwright | Buy |
| 2019-03-06 | Bestätigt | H.C. Wainwright | Buy |
| 2018-10-29 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2018-10-02 | Bestätigt | H.C. Wainwright | Buy |
| 2018-09-11 | Bestätigt | Argus | Buy |
| 2018-08-17 | Eingeleitet | Goldman | Neutral |
| 2018-08-08 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2018-06-21 | Eingeleitet | Argus | Buy |
| 2017-12-27 | Bestätigt | H.C. Wainwright | Buy |
| 2017-09-05 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-10-05 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-05 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2016-03-11 | Eingeleitet | Sidoti | Buy |
| 2016-03-03 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Ligand Pharmaceuticals Inc Aktie (LGND) Neueste Nachrichten
Moody Aldrich Partners LLC Buys Shares of 25,884 Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Calamos Advisors LLC Grows Stake in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Book value per share of Ligand Pharmaceuticals Incorporated – OTC:LGNZZ - TradingView — Track All Markets
Ligand Pharmaceuticals Earnings Notes - Trefis
Loss Report: How Ligand Pharmaceuticals Incorporated stock reacts to bond yieldsTrade Analysis Report & Daily Market Momentum Tracking - moha.gov.vn
Ligand Pharmaceuticals Incorporated $LGND Position Trimmed by Rice Hall James & Associates LLC - MarketBeat
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Releases FY 2025 Earnings Guidance - MarketBeat
Ligand Pharmaceuticals (LGND) Price Target Increased by 24.57% to 232.69 - MSN
Ligand Pharmaceuticals IncorporatedEquity Right (LGNDZ) Price Target Increased by 23.15% to 0.01 - Nasdaq
Ligand Pharmaceuticals Incorporated $LGND Stock Holdings Increased by Congress Asset Management Co. - MarketBeat
Published on: 2025-12-20 22:34:37 - Улправда
Will Ligand Pharmaceuticals Incorporated stock continue upward momentum2025 Earnings Impact & Community Consensus Stock Picks - Улправда
Can Ligand Pharmaceuticals Incorporated stock rebound after recent weaknessEarnings Performance Report & Free Verified High Yield Trade Plans - Улправда
How sustainable is Ligand Pharmaceuticals Incorporated stock dividend payoutJuly 2025 Action & Low Volatility Stock Recommendations - Улправда
Is Ligand Pharmaceuticals Incorporated stock positioned well for digital economyMarket Sentiment Report & Growth Focused Stock Pick Reports - DonanımHaber
Octavio Espinoza At Ligand Pharmaceuticals Capitalizes: Options Exercised, Resulting In $308K - Benzinga
Ligand Pharmaceuticals backs Athira Pharmas 90 million funding round - Traders Union
Will Ligand Pharmaceuticals Incorporated stock deliver better than expected guidance2025 Growth vs Value & Weekly High Conviction Ideas - Улправда
[Form 4] LIGAND PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
Published on: 2025-12-19 00:15:21 - Улправда
Why Ligand Pharmaceuticals Incorporated stock could outperform in 2025July 2025 Technicals & Proven Capital Preservation Methods - Улправда
Gains Recap: Will Ligand Pharmaceuticals Incorporated stock continue upward momentum2025 Trading Volume Trends & Safe Capital Investment Plans - Улправда
Ligand Pharmaceuticals (NASDAQ: LGND) outlines Athira investment update and disclosure channels - Stock Titan
Woodstock Corp Sells 9,472 Shares of Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
FY2026 Earnings Forecast for LGND Issued By Zacks Small Cap - MarketBeat
Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue? - Yahoo Finance
LIGAND PHARMACEUTICALS CFO Sells Shares - TradingView — Track All Markets
Ligand Pharmaceuticals (NASDAQ:LGND) CFO Sells $339,711.24 in Stock - MarketBeat
LGND: 2025 Analyst Day - Zacks Small Cap Research
Ligand Pharmaceuticals Incorporated $LGND Stock Holdings Raised by Ranger Investment Management L.P. - MarketBeat
Market Leaders: Is Ligand Pharmaceuticals Incorporated stock safe for conservative investorsPortfolio Gains Summary & Free Technical Confirmation Trade Alerts - moha.gov.vn
CFO Espinoza Files To Sell 1,804 Of Ligand Pharmaceuticals Inc [LGND] - TradingView — Track All Markets
What is HC Wainwright's Forecast for LGND FY2026 Earnings? - MarketBeat
RBC Capital Maintains Ligand Pharmaceuticals IncorporatedEquity Right (LGNDZ) Outperform Recommendation - Nasdaq
Norges Bank Acquires Shares of 14,073 Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
RBC Capital Maintains Ligand Pharmaceuticals (LGND) Outperform Recommendation - Nasdaq
Stifel Maintains Ligand Pharmaceuticals IncorporatedEquity Right (LGNYZ) Buy Recommendation - Nasdaq
Benchmark reaffirms Buy rating on Ligand Pharma stock with $220 target - Investing.com Canada
Oppenheimer reiterates Outperform rating on Ligand Pharma stock at $275 By Investing.com - Investing.com Canada
LGND: RBC Capital Raises Price Target, Maintains 'Outperform' Ra - GuruFocus
LGND: Stifel Raises Price Target to $230, Maintains 'Buy' Rating - GuruFocus
Stifel Nicolaus Boosts Ligand Pharmaceuticals (NASDAQ:LGND) Price Target to $230.00 - MarketBeat
RBC Lifts Price Target on Ligand Pharmaceuticals to $235 From $234, Keeps Outperform Rating - marketscreener.com
Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance - 富途牛牛
CFO Espinoza Surrenders 1,862 Of Ligand Pharmaceuticals Inc [LGND] - TradingView — Track All Markets
Ligand Pharma stock price target raised to $230 by Stifel on growth outlook - Investing.com Canada
Citigroup Initiates Coverage of Ligand Pharmaceuticals (LGND) with Buy Recommendation - Nasdaq
LIGAND PHARMACEUTICALS INCINTRODUCES 2026 REVENUE GUIDANCE OF $245-$285 MLN - 富途牛牛
Citigroup Initiates Coverage On LGND with a Buy Rating | LGND St - GuruFocus
Ligand Pharma sets 2026 outlook as Citi starts at buy on valuation - MSN
Finanzdaten der Ligand Pharmaceuticals Inc-Aktie (LGND)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):